ClinicalTrials.gg
Active, not recruitingNCT02549820CHOP_FETOUpdated Nov 4, 2026Results posted

Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia

An interventional study of GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter in Congenital Diaphragmatic Hernia and Pulmonary Hypoplasia, sponsored by Children's Hospital of Philadelphia. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Children's Hospital of Philadelphia · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.

Enrollment
16th of 36
28 · median 21
Started
2015
with 3 others
No phase
28 of 45
18 open now
Primary completion
2025-05
later than 1 of 27 live
Registered
12th of 45
by date
Lead sponsor
2 of 45
Children's Hospital of Philadelphia

Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 16th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2015, is one of 28 with no phase, reaches primary completion later than 1 of the 27 other live ones, and was the 12th registered.

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

Browse Hernias, Diaphragmatic, Congenital studies →

Open to participants now

24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, or all of them as a file.
02

Study summary

CDH is a birth defect characterized by the development, very early in gestation, of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen. As a result, the intestines and other organs in the abdomen can move into the chest and press on the developing lungs. This prevents the lungs from growing and developing normally.

In severe cases, CDH can lead to serious disease and death at birth. For these babies, treatment before birth may allow the lungs to grow enough before birth so these children are capable of surviving and thriving.

Read the detailed description

Study Summary

All patients will complete a standard prenatal evaluation at the Center for Fetal Diagnosis and Treatment (CFDT) to find out if they are candidates. The standard clinical assessments include: Medical history and Physical exam, Level II ultrasound, Fetal echocardiogram, Fetal magnetic resonance imaging (MRI), and a Psychosocial assessment.

If determined eligible, patients will be extensively counseled by the CFDT Team and those who choose to participate will provide written, informed consent for study enrollment.

Up to 25 women will be enrolled in the FETO study. The mother and her unborn baby will undergo two procedures. A balloon will be placed in the unborn baby's airway between 27+0/7 - 29+6/7 gestational age. The balloon blocks the airway and remains in place until balloon removal. The timing for balloon removal will be determined by the CFDT Management Team and can occur between 34 +0/7 - 34+6/7 gestational age.

Mothers enrolled in this study must remain near the fetal center, under close supervision, from the time of balloon placement through delivery in the Garbose Family Special Delivery Unit.

Weekly prenatal monitoring will occur after the first procedure at the CFDT and planned delivery will occur in the Garbose Family Special Delivery Unit at term.

Postnatal stabilization and subsequent surgery to repair the diaphragm will take place at CHOP.

Infants will be followed at CHOP at 6 months, 12 months, and 2 years of age and then long-term in the Pulmonary Hypoplasia Program at The Children's Hospital of Philadelphia.

03

Conditions studied

  • Congenital Diaphragmatic Hernia
  • Pulmonary Hypoplasia

Keywords

  • Congenital Diaphragmatic Hernia
  • Tracheal Occlusion
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pregnant women age 18 years and older, who are able to consent
  2. Singleton pregnancy

    Fetal:

  3. Normal Karyotype or chromosomal microarray with non-pathologic variants
  4. Diagnosis of Isolated Left CDH with liver up
  5. Gestation at enrollment prior to 29 weeks plus 5 days
  6. SEVERE pulmonary hypoplasia with Ultrasound Observed/Expected Lung-to-Head Ratio (O/E LHR) \< 25%

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women \< 18 years
  2. Maternal to fetoscopic surgery or severe maternal medical condition in pregnancy
  3. Technical limitations precluding fetoscopic surgery
  4. Rubber latex allergy
  5. Preterm labor, cervix shortened (\<15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa
  6. Psychosocial ineligibility, precluding consent
  7. Fetal Diaphragmatic hernia: right-sided or bilateral, major associated anomalies, isolated left-sided with the O/E LHR ≥ 25%
  8. Inability to remain at FETO site during time period of tracheal occlusion, delivery and postnatal care
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    FETO in CDH

    Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter

    Device: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter

Interventions

  • DeviceGoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter

    Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter

06

What researchers measure

Primary outcomes

  1. Successful Balloon Placement and Removal.

    Successful balloon placement and removal will be counted per patient. FETO insertion will be attempted up to 3 times in a single pregnant woman/ fetus. The maximum duration of balloon implantation, if placed at 27 weeks 0 days and removed in the 34th week, is 7 weeks. For those balloons placed later in gestation or removed earlier electively or emergently, the duration will be shorter.

    Time frame: 7 weeks

Secondary outcomes

  1. Fetal Lung Growth Due to FETO

    Fetal lung growth is assessed by O/E LHR measurement at time of balloon insertion (27w0d-29w6d) compared to O/E LHR measurement closest to 32w0d.

    Time frame: 7 weeks

  2. Survival Rate of FETO Patients

    This outcome measures the survival rate of all 14 maternal and 14 neonatal subjects until the end of the follow-up period (24 months corrected age, +/- one month)

    Time frame: Enrollment to end of the follow-up period (24 months corrected age, +/- one month)

07

Results

Posted Nov 4, 2026
Limitations and caveats
The sample size is small due to the relatively low incidence of severe CDH.

Participant flow

All patients referred to the CHOP Center for Fetal Diagnosis and Treatment (CFDT) with a confirmed diagnosis of CDH were screened for eligibility criteria.

Participant flow — Overall Study
MilestoneFETO in CDH - MaternalFETO in CDH - Fetal/Neonatal
Started1414
Completed1413
Not completed01
Withdrew: Death01

Outcome measures

PrimarySuccessful Balloon Placement and Removal.

Successful balloon placement and removal will be counted per patient. FETO insertion will be attempted up to 3 times in a single pregnant woman/ fetus. The maximum duration of balloon implantation, if placed at 27 weeks 0 days and removed in the 34th week, is 7 weeks. For those balloons placed later in gestation or removed earlier electively or emergently, the duration will be shorter.

Time frame:
7 weeks
Reported as:
Count of participants · Participants
Successful Balloon Placement and Removal.
ParticipantsFETO in CDH
Number of cases in which balloon was successfully placed and removed by puncture or fetoscopy9
Number of cases in which balloon was successfully placed and removed during C-section or EXIT5
SecondaryFetal Lung Growth Due to FETO

Fetal lung growth is assessed by O/E LHR measurement at time of balloon insertion (27w0d-29w6d) compared to O/E LHR measurement closest to 32w0d.

Time frame:
7 weeks
Reported as:
Count of participants · Participants
Fetal Lung Growth Due to FETO
ParticipantsFETO in CDH
Lung growth was < 5% change in O/E LHR3
Lung growth was 5-10% change in O/E LHR4
Lung growth was 10-15% change in O/E LHR3
Lung growth was 15-20% change in O/E LHR4
SecondarySurvival Rate of FETO Patients

This outcome measures the survival rate of all 14 maternal and 14 neonatal subjects until the end of the follow-up period (24 months corrected age, +/- one month)

Time frame:
Enrollment to end of the follow-up period (24 months corrected age, +/- one month)
Reported as:
Count of participants · Participants
Survival Rate of FETO Patients
ParticipantsFETO in CDH - MaternalFETO in CDH - Fetal/Neonatal
Survival Rate of FETO Patients1413

Adverse events

Collected over From enrollment until end of follow-up (24 months corrected age, +/- 1 month). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FETO in CDH1/28 (3.6%)28/28 (100%)13/28 (46.4%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventFETO in CDH
Respiratory distress/failure (Neonatal)Respiratory, thoracic and mediastinal disorders14/28
Pulmonary hypertension (Neonatal)Respiratory, thoracic and mediastinal disorders14/28
Gastroesophageal reflux disease (Neonatal)Gastrointestinal disorders14/28
Feeding difficulties (Neonatal)Gastrointestinal disorders14/28
Tracheomegaly and/or tracheomalacia (Neonatal)Respiratory, thoracic and mediastinal disorders13/28
Preterm premature rupture of membranesPregnancy, puerperium and perinatal conditions11/28
Preterm delivery ( < 37 weeks GA)Pregnancy, puerperium and perinatal conditions11/28
Preterm LaborPregnancy, puerperium and perinatal conditions10/28
Premature birth with a weight of < 2500 gm (Neonatal)Pregnancy, puerperium and perinatal conditions10/28
Chorioamniotic membrane separationPregnancy, puerperium and perinatal conditions7/28
Most frequent other events
Most frequent other events
EventFETO in CDH
Reactive airway disease (Neonatal)Respiratory, thoracic and mediastinal disorders6/28
Grade 1 germinal matrix bleed (Neonatal)Nervous system disorders4/28
Prenatal abdominal pain (Maternal)Pregnancy, puerperium and perinatal conditions2/28
Vasovagal reaction to epidural placement (Maternal)Vascular disorders1/28
Ileus (Maternal)Gastrointestinal disorders1/28
Preeclampsia without severe features (Maternal)Pregnancy, puerperium and perinatal conditions1/28

Baseline characteristics

Age, Customized
Age, Customized(Participants)FETO in CDH
Number of maternal participants ≥ 18 years of age14
Age Not Collected (Neonates Only)0
Sex: Female, Male
Sex: Female, Male(Participants)FETO in CDH
Sex of maternal participants — Female14
Sex of maternal participants — Male0
Sex of fetal/neonatal participants — Female6
Sex of fetal/neonatal participants — Male8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FETO in CDH
Race of maternal participants — American Indian or Alaska Native0
Race of maternal participants — Asian0
Race of maternal participants — Native Hawaiian or Other Pacific Islander0
Race of maternal participants — Black or African American1
Race of maternal participants — White12
Race of maternal participants — More than one race1
Race of maternal participants — Unknown or Not Reported0
Race of fetal/neonatal participants — American Indian or Alaska Native0
Race of fetal/neonatal participants — Asian0
Race of fetal/neonatal participants — Native Hawaiian or Other Pacific Islander0
Race of fetal/neonatal participants — Black or African American1
Race of fetal/neonatal participants — White12
Race of fetal/neonatal participants — More than one race1
Race of fetal/neonatal participants — Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FETO in CDH
Ethnicity of maternal participants — Hispanic or Latino1
Ethnicity of maternal participants — Not Hispanic or Latino13
Ethnicity of maternal participants — Unknown or Not Reported0
Ethnicity of fetal/neonatal participants — Hispanic or Latino2
Ethnicity of fetal/neonatal participants — Not Hispanic or Latino12
Ethnicity of fetal/neonatal participants — Unknown or Not Reported0
Maternal BMI
Maternal BMI(Participants)FETO in CDH
BMI 20-251
BMI 25-307
BMI 30-353
BMI 35-401
BMI 40-452
08

Study locations

1 site
09

References and documents

Publications

  • Jani JC, Nicolaides KH, Gratacos E, Valencia CM, Done E, Martinez JM, Gucciardo L, Cruz R, Deprest JA. Severe diaphragmatic hernia treated by fetal endoscopic tracheal occlusion. Ultrasound Obstet Gynecol. 2009 Sep;34(3):304-10. doi: 10.1002/uog.6450. PubMed 19658113 ↗
  • Deprest J, Nicolaides K, Done' E, Lewi P, Barki G, Largen E, DeKoninck P, Sandaite I, Ville Y, Benachi A, Jani J, Amat-Roldan I, Gratacos E. Technical aspects of fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia. J Pediatr Surg. 2011 Jan;46(1):22-32. doi: 10.1016/j.jpedsurg.2010.10.008. PubMed 21238635 ↗
  • Deprest JA, Gratacos E, Nicolaides K, Done E, Van Mieghem T, Gucciardo L, Claus F, Debeer A, Allegaert K, Reiss I, Tibboel D. Changing perspectives on the perinatal management of isolated congenital diaphragmatic hernia in Europe. Clin Perinatol. 2009 Jun;36(2):329-47, ix. doi: 10.1016/j.clp.2009.03.004. PubMed 19559323 ↗
  • Danzer E, Hedrick HL. Controversies in the management of severe congenital diaphragmatic hernia. Semin Fetal Neonatal Med. 2014 Dec;19(6):376-84. doi: 10.1016/j.siny.2014.10.001. Epub 2014 Nov 7. PubMed 25454678 ↗
  • Deprest J, Brady P, Nicolaides K, Benachi A, Berg C, Vermeesch J, Gardener G, Gratacos E. Prenatal management of the fetus with isolated congenital diaphragmatic hernia in the era of the TOTAL trial. Semin Fetal Neonatal Med. 2014 Dec;19(6):338-48. doi: 10.1016/j.siny.2014.09.006. Epub 2014 Nov 11. PubMed 25447987 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of May 2025 and a completion of Jul 2027. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2026, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2015
First posted
Sep 15, 2015
Start
Jul 2015
Primary completionActual
May 1, 2025
CompletionEst.
Jul 2027
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Enrollment
14→28
Nov 4, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedSuccessful balloon placementBalloon Placement and removalRemoval.Time frame: 7 weeks
Nov 4, 2026
Secondary outcomes
2 added
What changed in the outcomes
  • AddedFetal Lung Growth Due to FETOTime frame: 7 weeks
  • AddedSurvival Rate of FETO PatientsTime frame: Enrollment to end of the follow-up period (24 months corrected age, +/- one month)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Enrollment 14→28
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedSuccessful balloon placementBalloon Placement and removalRemoval.Time frame: 7 weeks
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedFetal Lung Growth Due to FETOTime frame: 7 weeks
    • AddedSurvival Rate of FETO PatientsTime frame: Enrollment to end of the follow-up period (24 months corrected age, +/- one month)
    + 3 other changes: verification date, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02549820
Responsible party
Holly L Hedrick, MD (Principal Investigator, Professor of Surgery, Children's Hospital of Philadelphia) — Principal investigator
First posted
Sep 15, 2015
Start date
Jul 2015
Primary completion
May 1, 2025
Completion
Jul 2027 (estimated)
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Holly L Hedrick, MD
principal investigator · Children's Hospital of Philadelphia and the Center for Fetal Diagnosis and Treatment

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion